Although elevation of the blood glucose level is a causal adverse effect of treatment with interferon (IFN), the precise underlying molecular mechanism is largely unknown. We examined the effects of type I and type II IFN (IFN-␤ and IFN-␥) on insulin-induced metabolic signaling leading to glucose uptake in 3T3-L1 adipocytes. IFN-␤ suppressed insulininduced tyrosine phosphorylation of IRS-1 without affecting its expression, whereas IFN-␥ reduced both the protein level and tyrosine phosphorylation. Although both IFNs stimulated phosphorylation of STAT1 (at Tyr 701 ) and STAT3 (at Tyr 705 ) after treatment for 30 min, subsequent properties of induction of the SOCS isoform were different. IFN-␤ preferentially induced SOCS1 rather than SOCS3, whereas IFN-␥ strongly induced SOCS3 expression alone. In addition, adenovirus-mediated overexpression of either SOCS1 or SOCS3 inhibited insulin-induced tyrosine phosphorylation of IRS-1, whereas the reduction of IRS-1 protein was observed only in SOCS3-expressed cells. Notably, IFN-␤-induced SOCS1 expression and suppression of insulin-induced tyrosine phosphorylation of IRS-1 were attenuated by siRNA-mediated knockdown of STAT1. In contrast, adenovirusmediated expression of a dominant-negative STAT3 (F-STAT3) attenuated IFN-␥-induced SOCS3 expression, reduction of IRS-1 protein, and suppression of insulin-induced glucose uptake but did not have any effect on the IFN-␤-mediated SOCS1 expression and inhibition of insulin-induced glucose uptake. Interestingly, pretreatment of IFN-␥ with IL-6 synergistically suppressed insulin signaling, even when IL-6 alone had no significant effect. These results indicate that type I and type II IFN induce insulin resistance by inducing distinct SOCS isoforms, and IL-6 synergistically augments IFN-␥-induced insulin resistance by potentiating STAT3-mediated SOCS3 induction in 3T3-L1 adipocytes.
for the treatment of cancer, tuberculosis, and hepatic or chronic granulomatous disease (16) . During this treatment, adverse effects on glucose metabolism have been recognized. Thus, the incidence of diabetes mellitus is known to increase during treatment with IFNs (20) . Two independent mechanisms of glucose dysregulation caused by IFNs have been proposed, one of which is the immune response of the pancreas, leading to insulitis and type 1 diabetes (5, 36) . Along this line, transgenic mice expressing either IFN-␣ or IFN-␤ in pancreatic ␤-cells have developed hypoinsulinemic diabetes (21, 36) . The other mechanism is the enhancement of peripheral insulin resistance, which has been demonstrated by the glucose tolerance test and insulin clamp studies (13) .
Both type I and type II IFNs have been shown to activate the signal transducer and activator of the transcription (STAT) family of proteins via the Janus tyrosine kinase (JAK) family through cognate IFN-␣ and IFN-␥ receptors, respectively (30, 31) . After activation, cytoplasmic STAT transcription factors homodimerize or heterodimerize, translocate to the nucleus, and promote transcription of a family of suppressor of cytokine signaling (SOCS) (30) . SOCS was identified originally as a protein induced by cytokines that activate JAK-STAT pathways and is implicated in the negative feedback regulation of cytokine signals (3, 18, 27, 34) . Upregulation of SOCS1 and SOCS3 was demonstrated in the liver, muscle, and adipose tissues of bacterial LPS-treated mice and obese db/db mice (37) . In addition, SOCS is known to interfere not only with the JAK-STAT pathway but also with insulin signaling (27, 29, 37) . Adenovirus-mediated overexpression of SOCS3 suppressed insulin signaling and glucose uptake, resulting in systemic insulin resistance in mice (37) . Similarly, adenovirusmediated liver-specific overexpression of SOCS1 caused the elevation of blood glucose and insulin resistance (29) , whereas SOCS1-deficient mice demonstrated decreased blood glucose levels by sustained phosphorylation of insulin receptor substrate-1 (IRS-1) in response to insulin (12) .
Adipose tissue is one of the principle target tissues of insulin and contributes to maintaining glucose homeostasis and is very important for insulin resistance in obesity (9) . IFN-␥ is known to induce phosphorylation and activation of both STAT1 and STAT3 in 3T3-L1 and rat adipocytes (35) . A recent study suggested the crucial role for JAK1-STAT1 in IFN-␥-induced attenuation of insulin signaling and suppression of differentiation from preadipocyte in human adipocytes (14) . However, a number of previous studies indicate an important role of STAT3 and SOCS3 in the development of insulin resistance in the adipocyte and liver (11, 33, 37, 38) . In addition, the molecular mechanism by which IFN-␤ causes insulin resistance in adipocytes is largely unknown. Furthermore, the relative difference between type I and type II IFN-induced SOCS expressions and their inhibitory effects on insulin signaling has not yet been characterized.
Therefore, in the present study, we investigated the function of STATs (in particular STAT3) in the development of IFNinduced insulin resistance. We directly compared the impact on IFN-␤ and IFN-␥ in insulin signaling in 3T3-L1 adipocytes and investigated the molecular mechanism by which these IFNs cause insulin resistance by interacting with different isoforms of SOCS. In addition, we sought to identify which STAT/ SOCS pathway is relevant to insulin resistance induced by each type of IFN.
MATERIALS AND METHODS

Materials.
Human recombinant insulin was provided by Novo Nordisk Pharmaceutical (Copenhagen, Denmark). Mouse IFN-␤ and mouse IFN-␥ were provided by Toray Industries (Tokyo, Japan) and Hayashibara Biochemical Laboratories (Okayama, Japan), respectively. Mouse IL-6 was purchased from Sigma-Aldrich Japan (Tokyo, Japan). A polyclonal anti-insulin receptor (IR)␤ antibody, polyclonal anti-Tyr 612 phosphospecific IRS-1 antibody, monoclonal anti-Akt antibody, monoclonal anti-phosphotyrosine (PY) antibody, polyclonal anti-SOCS3 antibody, polyclonal anti-aP2 antibody, polyclonal anti-CCAAT/enhancer binding protein (C/EBP)-␣ antibody, polyclonal anti-peroxisome proliferator-activated receptor (PPAR)␥ antibody, polyclonal anti-sterol regulatory element-binding protein (SREBP)-1 antibody, and polyclonal anti-GLUT1 were from Santa Cruz Biotechnology (Santa Cruz, CA). A polyclonal anti-IRS-1 antibody was from Millipore (Billerica, MA). The polyclonal anti-Ser 307 phosphospecific IRS-1 antibody, polyclonal anti-Tyr 612 phosphospecific IRS-1 antibody, polyclonal anti-Ser 473 phosphospecific Akt antibody, polyclonal anti-STAT1 antibody, polyclonal anti-Tyr 701 phosphospecific STAT1 antibody, polyclonal anti-STAT3 antibody, polyclonal antiTyr 705 phosphospecific STAT3 antibody, polyclonal anti-Ser 727 phosphospecific STAT3 antibody, and polyclonal anti-␤-actin antibody were from Cell Signaling Technology (Beverly, MA). A polyclonal anti-SOCS1 antibody was from Immuno Biological Laboratory (Fujioka, Japan). A monoclonal anti-GLUT4 antibody was from Abcam (Cambridge, UK). Dulbecco's modified Eagle's medium (DMEM) was obtained from Life Technologies (Carlsbad, CA). Trypan blue solution (0.4%) was from Wako Pure Chemical Industries, (Osaka, Japan). All other reagents were of analytical grade and purchased from Sigma-Aldrich Japan or Wako Pure Chemical Industries.
Culture and differentiation of 3T3-L1 adipocytes. 3T3-L1 preadipocytes were grown and passaged in DMEM supplemented with 10% newborn calf serum. Cells 2-3 days postconfluence were used for differentiation. The differentiation medium contained 10% fetal calf serum (FCS), 250 nM dexamethasone, 0.5 mM isobutylmethylxanthine, and 500 nM insulin. After 3 days of treatment, the differentiation medium was replaced with postdifferentiation medium containing 10% FCS and 500 nM insulin. After 3 days of incubation, postdifferentiation medium was replaced with DMEM supplemented with 10% FCS (32, 41, 42 (7) . The cDNAs encoding SOCS1 and SOCS3 were provided by Dr. K. Ueki (University of Tokyo) (37) . A control LacZ virus encoding ␤-galactosidase was constructed as described previously (32, 41, 42) . WT-STAT3 or F-STAT3 was transiently expressed in differentiated 3T3-L1 adipocytes by means of adenovirus-mediated gene transfer (42) . In brief, a multiplicity of infection of 40 plaque-forming units (pfu)/cell was used to infect 3T3-L1 adipocytes, with the virus being left on the cells for 16 h prior to removal. Subsequent experiments were conducted 24 -48 h after initial addition of the virus. The efficiency of adenovirus-mediated gene transfer was ϳ95%.
Immunoprecipitation and Western blotting. 3T3-L1 adipocytes grown in six-well multiplates were serum starved for 16 h without or with 200 or 1,000 IU/ml IFN-␤, 200 or 1,000 IU/ml IFN-␥, 10 ng/ml IL-6, or IFN-␥ plus IL-6 and stimulated with 1.7 nM insulin for 5 min. The cells were lysed in a buffer containing 20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM sodium deoxycholate, 1 mM ␤-glycerophosphate, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na 3VO4, 50 mM sodium fluoride, 10 g/ml aprotinin, and 10 M leupeptin, pH 7.4, for 15 min at 4°C. Lysates obtained from the same number of cells were centrifuged to remove insoluble materials. The supernatants (100 g of protein) were immunoprecipitated with the indicated antibodies or precipitated with glutathione sepharose beads for 2 h at 4°C. The precipitates or whole cell lysates were then separated by 7.5% SDS-PAGE and transferred onto polyvinylidene difluoride membranes using Bio-Rad Transblot equipment. The membranes were blocked in a buffer containing 50 mM Tris, 150 mM NaCl, 0.1% Tween 20, and 2.5% bovine serum albumin or 5% non-fat milk, pH 7.5, for 2 h at 20°C. The membranes were then probed with the specified antibodies (1:500 dilutions for anti-SOCS1, SOCS3, and phospho-Ser 307 IRS-1 antibodies and 1:1,000 dilutions for other antibodies) for 2 h at 20°C or for 16 h at 4°C. After being washed in a buffer containing 50 mM Tris, 150 mM NaCl, and 0.1% Tween 20, pH 7.5, the membranes were incubated with horseradish peroxidase-linked second antibody followed by enhanced chemiluminescence detection using ECL reagent according to the manufacturer's instructions (GE Healthcare Bioscience, Uppsala, Sweden). Densitometric analysis was conducted directly using the blotted membrane by utilizing an LAS-4000 lumino-image analyzer system (Fujifilm, Tokyo, Japan) (40, 41) .
Small interfering RNA-mediated knockdown of STAT1, SOCS1, and SOCS3. Gene knockdown by small interfering RNA (siRNA) was performed by Lonza Nucleofector system (Amaxa), as described previously (39, 42) . The electroporation was conducted according to the manufacturer's instructions. In brief, differentiated 3T3-L1 adipocytes were scraped with 0.25% trypsin and 0.5 mg/ml collagenase. After being washed with PBS, cells were mixed with Nucreofector solution and 1 g siRNA, and electroporation was conducted. The siRNA sense sequence for STAT1 was 5=-GCCAAGGAGGAGAU-CUCCGAAGAUA-3=. The siRNA sense sequence for SOCS1 was 5=-GGACAUGGCAGGAGUGUUU-3=. The siRNA sense sequence for SOCS3 was 5=-GGACAUGGCAGGAGUGUUU-3=. Stealth RNAi negative control medium GC duplex (Invitrogen) was used as control scramble siRNA. Cells were harvested and examined 24 -48 h postelectroporation.
Measurement of insulin-induced 2-deoxyglucose uptake. 3T3-L1 adipocytes grown in six-multiwell plates were serum starved for 16 h without or with 1,000 IU/ml IFN-␤ or IFN-␥ and further incubated in Krebs-Ringer phosphate-HEPES buffer containing 1% bovine serum albumin for 2 h at 37°C. The cells were subsequently stimulated with various concentrations of insulin. Statistical analyses. The data are shown as means Ϯ SE. P values were determined by Bonferroni correction for comparison against the control or by Student-Newman-Keuls multiple comparison test to compare multiple conditions, as appropriate, after ANOVA, and differences among groups were considered significant when P Ͻ 0.05.
RESULTS
IFN-␤ and IFN-␥ attenuate insulin-induced phosphorylation of IRS-1 by a distinct mechanism.
We examined the effect of IFN on the protein amount and insulin-induced tyrosine phosphorylation of IR ( (Fig. 2D ). The amount of IRS-1 decreased to 26.3 Ϯ 3.1% of the control value after treatment for 24 h. IFN-␥ also apparently reduced the levels of tyrosine phosphorylation of IRS-1 (Fig. 2E) . However, the tyrosine phosphorylation of IRS-1, normalized to IRS-1 protein levels, was not affected significantly by the treatment with (data not shown), indicating that these phosphorylations of IRS-1 at Ser residues are not responsible for the reduction of insulin-induced tyrosine phosphorylation of IRS-1. Although we utilized 1,000 IU/ml of IFN to clarify the distinct signaling property of each IFN, similar inhibitory effects on the insulin signaling were obtained using a lower dose of IFN (200 IU/ml) (Supplemental Fig. S1 ; Supplemental Material for this article is available online at the AJP-Endocrinology and Metabolism website).
Both IFN-␤ and IFN-␥ similarly phosphorylate STAT1 and STAT3 but induce a distinct isoform of SOCS. Numbers of previous studies indicate an important role of STAT3 and SOCS3 in the development of insulin resistance in the adipocyte and liver (11, 33, 37, 38) . However, a recent study suggested that IFN-␥ activates STAT1 and suppresses adipocyte differentiation (14) . Since STAT1 and STAT3 are known to be important for mediating IFN signaling (17, 35) , we next examined the effect of IFN-␤ or IFN-␥ on the phosphorylation of STAT1 and STAT3. The protein amount of STAT3 was not altered following 0.5 or 1 h of treatment with both IFN-␤ and IFN-␥ (Fig. 3, A and D) , whereas marked phosphorylation of STAT3 at Tyr 705 residue was observed at these time points (Fig. 3, B and E) . In contrast, slight but significant upregulation of STAT3 was observed following 24 h of treatment with IFN-␤ or 16 -24 h of treatment with IFN-␥ (Fig. 3, A and D (Fig. 4A) , and importantly, this expression was preceded by the phosphorylation of STAT1 at Tyr 701 and STAT3 at Tyr 705 , as described above. IFN-␤ also stimulated the expression of SOCS3, although the degree of the expression level was lower than that of SOCS1 (Fig. 4B) . On the other hand, IFN-␥ markedly induced the expression of SOCS3, reaching its peak at 4 h, whereas it did not affect the expression of SOCS1 (Fig. 4, C and D) .
Involvement of STAT3 in SOCS3 expression by IFN. To investigate the involvement of STAT3 in the induction of SOCS1 and SOCS3 by IFNs, we expressed WT-STAT3 and a dominant-negative mutant F-STAT3, in which Tyr 705 residue was replaced with phenylalanine (7), and examined the effect of the expression on IFN-␤-or IFN-␥-induced expression of SOCS proteins (Fig. 5) . Fivefold more WT-STAT3 and F-STAT3 than endogenous STAT3 were expressed by the adenoviral expression at the multiplicity of infection of 40 pfu/ cell. IFN-␤-induced expression of SOCS1 was not affected by the expression of either WT-STAT3 or F-STAT3 (Fig. 5A) , and SOCS1 expression was not altered in IFN-␥-treated cells expressing either WT-or F-STAT3 (Fig. 5C ). On the other hand, IFN-␤-and IFN-␥-induced upregulation of SOCS3 was inhibited by the expression of F-STAT3 but was not affected by the expression of WT-STAT3 (Fig. 5, B and D) . These results indicate that STAT3 is involved in both IFN-␤-and IFN-␥-induced expression of SOCS3 but not SOCS1.
Effect of SOCS expression on insulin signaling and SOCS knockdown on IFN-induced insulin resistance.
To clarify the impact of SOCS1 and SOCS3 on the insulin signaling system, we examined directly the effect of SOCS1 and SOCS3 expressions on insulin-induced tyrosine phosphorylation and the amount of IRS-1 (Fig. 6, A-C) . Overexpression of either SOCS1 or SOCS3 significantly suppressed insulin-induced tyrosine phosphorylation of IRS-1 (Fig. 6A) . Interestingly, although overexpression of SOCS1 did not affect the amount of IRS-1 protein, SOCS3 expression significantly reduced the protein level of IRS-1 in a time-dependent manner 36 h postinfection (Fig. 6, B and C) .
To further study the impact of IFN-induced SOCS expression on the development of insulin resistance, we examined the effect of knockdown of SOCS1 and SOCS3 on the IFNinduced alteration of insulin signaling (Fig. 6, D and E) . Specific knockdown of SOCS1 and SOCS3 by siRNA was observed following treatment with both IFNs for 4 h (Fig. 6D) , at which the maximal expression of SOCS was obtained in the control cells (Fig. 4) . Importantly, insulin-induced tyrosine phosphorylation of IRS-1 blunted by IFN-␤ was recovered by the knockdown of SOCS1. In contrast, the protein reduction and subsequent attenuation of insulin-induced tyrosine phosphorylation of IRS-1 by IFN-␥ were ameliorated by the knockdown of SOCS3 (Fig. 6E) . These results further strengthen our view that IFN-␤ and IFN-␥ develop insulin resistance through the distinct SOCS isoform.
Effect of IFN-␤ and IFN-␥ on insulin-induced Akt phosphorylation and glucose uptake. Since Akt is an important downstream molecule of the IRS-phosphatidylinositol 3-kinase pathway implicated in insulin-induced glucose uptake (32), we next examined the effect of IFN-␤ or IFN-␥ on insulin-induced phosphorylation of Akt (Fig. 7, A and B) . Both IFN-␤ and IFN-␥ effectively reduced the insulin-induced phosphorylation of Akt in a time-dependent manner. Akt phosphorylation was reduced to 49.1 Ϯ 11.3 and 48.0 Ϯ 2.4% of the control value after treatment for 24 h. The total amount of Akt was unaffected by treatment with both IFNs. Since treatment with IFN-␥ preferentially stimulated the expression of SOCS3 through the STAT3-dependent pathway (Fig. 5) , we examined the effect of WT-STAT3 and F-STAT3 expression on the IRS-1 amount, IRS-1 tyrosine phosphorylation, and Akt phosphorylation. IFN-␥-induced reduction of the amount of IRS-1, insulin-stimulated tyrosine phosphorylation of IRS-1, and phosphorylation of Akt were protected by the expression of F-STAT3 (Fig. 7, C-E) . These results reinforce our view that STAT3-mediated SOCS3 expression is a crucial mechanism for IFN-␥-induced insulin resistance. In contrast, the expression of F-STAT3 had only a slight impact on IFN-␤-induced alteration of the phosphorylation of IRS-1 and Akt (data not shown).
IFN-␤ preferentially induced SOCS1 expression and caused insulin resistance independently of the expression of F-STAT3 (Figs. 4, 5, and 7) . Since the principal role of STAT1 in SOCS1 expression and STAT3 in SOCS3 expression has been shown (6), we further examined the role of STAT1 in the development of IFN-induced insulin resistance (Supplemental Fig. S3 ). Knockdown of STAT1 significantly suppressed the IFN-␤-induced SOCS1 induction (Supplemental Fig. S3A ). In contrast, the knockdown of STAT1 did not affect SOCS3 induction by both IFN-␤ and IFN-␥ (Supplemental Fig. S3C ). In accord with these results, the knockdown of STAT1 recovered only the IFN-␤-induced attenuation of IRS-1 phosphorylation and did not have any effect on the IFN-␥-induced insulin resistance (Supplemental Fig. S3, B and D) . These results indicate that IFN-␤ suppresses insulin-induced tyrosine phosphorylation of IRS-1 mainly through the STAT1/SOCS1 pathway, and IFN-␥ suppresses insulin signaling independently of STAT1/SOCS1 pathway in 3T3-L1 adipocytes.
Moreover, we measured directly the effect of IFN-␤ and IFN-␥ on insulin-induced 2DG uptake (Fig. 8) . Treatment with both IFN-␤ and IFN-␥ significantly suppressed insulin-induced glucose uptake, and the inhibitory effect was greater with treatment with IFN-␥ than it was with IFN-␤. Interestingly, the expression of F-STAT3 effectively ameliorated the reduction of the glucose uptake in IFN-␥-treated cells but not in IFN-␤-treated cells.
IFN-␥ and IL-6 synergistically inhibit insulin signaling. Proinflammatory cytokines cooperate with each other in eliciting their activity. IL-6 is known to induce insulin resistance by reducing IRS-1-and GLUT4 in adipose tissue (28) . Since IL-6 is also a potent activator of the JAK2-STAT3 pathway and induces SOCS3 more preferentially than SOCS1 (34), we finally examined the cooperative effect of IFN-␥ with low-dose IL-6 treatment, in which IL-6 itself does not suppress insulin signals (Fig. 9) . Treatment with low-dose IL-6 alone for 1 or 24 h had no significant effect on the expression level of IRS-1 (Fig. 9A) , insulin-induced tyrosine phosphorylation of IRS-1 (Fig. 9B) , or Akt phosphorylation (Fig. 9C) ; however, compared with the effect of IFN-␥ alone, these insulin signals were profoundly suppressed when cells were coincubated with IL-6 and IFN-␥. After cotreatment for 24 h, the amounts of IRS-1, IRS-1 tyrosine phosphorylation, and Akt phosphorylation were reduced to 14.8 Ϯ 7.2, 7.7 Ϯ 6.9, and 15.8 Ϯ 9.1%, respectively, of the control value. We further examined the protein amounts and phosphorylation levels of STAT3 (Fig. 9, D and E) and protein levels of SOCS3 (Fig. 9F) by cotreatment with IFN-␥ and IL-6. The total amount of STAT3 was unaffected, but phosphorylation levels of STAT3 tended to be enhanced by the cotreatment. Moreover, interestingly, a significant additive effect on the expression of SOCS3 was observed. In contrast, the synergistic effect of IFN-␤ and IL-6 was not observed (data not shown), possibly because of the low levels of SOCS3 induction by IFN-␤ compared with IFN-␥ (Fig. 4) .
Effect of IFN-␤ and IFN-␥ on the cell viability or differentiation status in adipocytes.
Since a recent study indicated that IFN-␥ attenuated insulin signaling by suppressing differentiation status in human adipocytes (14), we finally examined the influence of IFN (1,000 IU/ml) on the cell viability and differentiation in 3T3-L1 adipocytes. In the trypan blue staining test, the numbers of living cells treated without or with IFN-␤ and IFN-␥ for 48 h were 69.6 Ϯ 3.7, 66.9 Ϯ 0.5, and 70.1 Ϯ 2.2%, indicating that the cell viability was not affected by the IFN treatment (Supplemental Fig. S4A ). In addition, neither IFN-␤ nor IFN-␥ treatment for Յ48 h affected lipid accumulation evaluated by Oil Red O staining in fully differentiated 3T3-L1 adipocytes (Supplemental Fig. S4B ). The protein amounts of adipocyte differentiation markers C/EBP-1␣, PPAR␥, and SREBP-1c, in addition to GLUT1 and GLUT4, were not affected by the treatment Յ24 h (Supplemental Fig. S4C ). These results indicate that treatment with 1,000 IU/ml of IFN for Յ24 h did not affect the differentiation status in 3T3-L1 adipocytes in the present experimental condition.
DISCUSSION
IFNs are known to cause glucose dysregulation and increase the risk of diabetes mellitus (5) . Type I and II IFN bind to the cognitive receptor IFN-␣R1/2 and IFN-␥R1/2, followed by the activation of receptor-coupled kinase JAK1/Tyk2 and JAK1/ JAK2, respectively (30, 31) . Activated JAK1 and Tyk2 by type I IFN phosphorylate and activate STAT proteins (30, 31) . Based on studies of STAT1-deficient mice, STAT1 plays a major role in either the IFN-␣-or IFN-␥-mediated biological response in immune cells (15) . STAT3 is also important for the immune response mediated by IFNs (24, 31) . In addition, IFN-induced STAT signaling is known to induce mainly SOCS1 and SOCS3 proteins (27, 30, 34) ; however, the relative importance of different STAT/SOCS signaling pathways in both type I and type II IFN-mediated insulin resistance in adipocytes is largely unknown. Therefore, in the present study, we provided a direct comparison of the signaling properties of IFN-␤ and IFN-␥ to inhibit the insulin action in 3T3-L1 adipocytes. We found that IFN-␤ and IFN-␥ differently modulate insulin signaling by inducing different types of SOCS proteins.
Previous studies have shown that SOCS proteins are implicated in insulin resistance (27, 29, 37) . Overexpression of SOCS1 and SOCS3 inhibited insulin-induced 2DG uptake in 3T3-L1 adipocytes (37) . Liver-specific overexpression of SOCS1 in mice resulted in impaired glucose tolerance via the degradation of IRS-1 and IRS-2 in the liver (29) . In addition, the expression of SOCS1 and SOCS3 proteins was elevated in the liver and muscle of LPSinjected mice and diabetic db/db mice (37). Expression of SOCS3 was also increased in the liver of patients with metabolic syndrome (22) . In the present study, we demonstrated that treatment with both IFN-␤ and IFN-␥ effectively suppressed insulin signaling, leading to the reduction of glucose uptake via the induction of SOCS expression in 3T3-L1 adipocytes (Figs. 2-4, 7, and 8) . Interestingly, IFN-␤ preferentially induced the expression of SOCS1 rather than SOCS3 and suppressed insulin-induced tyrosine (Fig. 6E) . Along these lines, adenovirus-mediated overexpression of SOCS3, but not SOCS1, effectively reduced the amount of IRS-1, whereas the expression of SOCS1 and SOCS3 markedly suppressed insulin-induced tyrosine phosphorylation of IRS-1 in both cases (Fig. 6) . These results are consistent with the previous report that transgenic mice overexpressing SOCS3 demonstrated the decreased expression level of IRS-1 and subsequent reduction of insulin signaling, leading to the impairment of insulin-induced glucose uptake in adipose tissue (33) .
In addition, the expression of a dominant-negative STAT3 (F-STAT3) significantly suppressed IFN-␤-and IFN-␥-induced expression of SOCS3 but not SOCS1 (Fig. 5) . IFN-␥-induced degradation of IRS-1, reduction of insulin-induced phosphorylation of IRS-1 and Akt, and decrease in glucose uptake were effectively ameliorated by the expression of F-STAT3 (Figs. 7 and 8) ; therefore, IFN-␥-mediated insulin resistance appears to be caused mainly by the STAT3/SOCS3 pathway. In contrast, knockdown of STAT1 suppressed IFN-␤-induced upregulation of SOCS1 (but not SOCS3) and ameliorated subsequent inhibition of insulininduced tyrosine phosphorylation of IRS-1 ( Supplemental  Fig. S3) ; therefore, IFN-␤-induced insulin resistance may be mediated predominantly via the STAT1/SOCS1 pathway. These results are consistent with a canonical model proposing the principal role of STAT1 in the SOCS1 expression and STAT3 in the SOCS3 expression (6) . The underlying mechanism of type-specific utilization of the STAT1/ SOCS1 or STAT3/SOCS3 pathway by different IFNs is unknown. Serine phosphorylation of STAT might be related to the selective induction of SOCS isoform, since the time course of STAT3 phosphorylation at Ser 727 by IFN-␤ and IFN-␥ was apparently different, regardless of the similar phosphorylation at Tyr 705 residue (Fig. 3) . In addition, a posttranscriptional mechanism might be involved, at least in part, in high-level expression of SOCS3 protein under IFN-␥. In this regard, treatment with IFN-␥ induced both SOCS1 and SOCS3 mRNA expressions, contrary to the protein levels. On the other hand, IFN-␤ preferentially induced mRNA expression of SOCS1 rather than SOCS3, consistent with the results of protein levels (data not shown). A recent study showed that treatment with IFN-␥ inhibited insulin signaling in the human adipocytes by causing robust STAT1 phosphorylation and SOCS1 mRNA expression and by suppressing the differentiation of preadipocytes into adipocytes (14) . Treatment with human IFN-␥ for 24 h suppressed insulin-induced glucose uptake via suppressed expression of PPAR␥, insulin receptor, IRS-1, and GLUT4 mRNA, possibly because of the promotion of the dedifferentiation in human adipocytes (14) . In the present study, we observed that treatment with murine IFN-␥ for 24 h inhibited insulin action without affecting differentiation status in 3T3-L1 adipocytes (Supplemental Fig. S4 ). In contrast, treatment with IFN-␥ for longer than 48 h has been shown to suppress glucose uptake by the mechanism of promotion of dedifferentiation in 3T3-L1 adipocytes (43) . Thus, it appears that IFN-␥ induces insulin resistance directly through the STAT/SOCS pathway and indirectly through suppression of adipocyte differentiation (4, 14, 43) . In the present study, we could clarify the signal transduction mechanism underlying IFN-␥-induced insulin resistance independently of adipocyte differentiation status in 3T3-L1 adipocytes. It is of note that the difference of speciesspecific activation process after IFN treatment (10, 30) may contribute to the discrepancy between our results and previous findings (14) .
It is known that IFNs activate alternative pathways in addition to the STAT/SOCS pathway in relation to insulin signaling (23, 25) . Thus, IFN-␥ is reported to activate phosphatidylinositol 3-kinase-Akt and MAP kinase pathways through receptor-bound JAK2 (23, 25) . Since treatment with either IFN-␤ or IFN-␥ did not induce the phosphorylation of Akt (Fig. 7) and MAP kinase (data not shown), at least in our study, we consider that the inhibitory effect of IFNs on insulin signaling does not depend on the alternative pathway in adipocytes.
Serum concentrations of multiple cytokines are known to be elevated in response to various stresses, including virus infection, (17, 33) . IL-6 is one of the proinflammatory cytokines implicated in the pathogenesis of insulin resistance (28) . Treatment with IL-6 decreased the expression of IRS-1 and insulin-induced glucose uptake in 3T3-L1 adipocytes (28) . Insulin-induced expression of SOCS3 is synergistically augmented by cotreatment with IL-6 in 3T3-L1 adipocytes (1) . In addition, increased IL-6 was reported in the serum of hepatitis C virus-infected subjects (2) and in the fat tissue of insulin-resistant subjects (28) . Since IL-6 plays a crucial role in the state of insulin resistance, we examined the effect of cotreatment with IFN and IL-6 on insulin signaling. Compared with IFN-␥ alone, insulin signaling was further suppressed in cells coincubated with IFN-␥ and IL-6 despite no significant effect with IL-6 alone (Fig. 9) . Since proinflammatory cytokines are generally known to enhance the production of other cytokines, we could not exclude the possibility that other factors recruited in the treatment with IFN activate STAT3 and affect the insulin sensitivity. More attention should be paid to clinical use of IFNs to prevent the augmentation of insulin resistance caused by proinflammatory cytokines in viral infections with hepatitis.
Recently, the accumulation of T lymphocytes has been shown in adipose tissues following high-fat feeding (19, 26, 44 ). Accumulation appears to impair systemic insulin sensitivity by causing macrophage infiltration and inflammation (28) . IFN-␥ is synthesized in immune cells, including CD4 Th1 cells and CD8 cytotoxic T cells (30) . Indeed, the expression of IFN-␥ has been shown to be increased in the adipose tissue of obese mice (26) . Importantly, improved systemic glucose tolerance is observed with lower expression levels of tumor necrosis factor-␣ and monocyte chemoattractant protein-1 in adipose tissue in obese IFN-␥-deficient mice (26) . On the basis of this, we consider that IFN-␥-mediated insulin resistance in adipose tissue may be one of the fundamental events in obesity-related glucose dysregulation.
In conclusion, the present results indicate first that both type I and type II IFNs induce insulin resistance by the distinct STAT/ SOCS pathway and that IFN-␥ induces insulin resistance by potentiating STAT3-mediated SOCS3 induction in 3T3-L1 adipocytes. In addition, we provided the evidence demonstrating the underlying molecular mechanism of IFN-␤-induced insulin resistance via the STAT1/SOCS1 pathway (Fig. 10) . These findings appear to contribute further to understanding the mechanism of insulin resistance in the inflammation and under the condition of treatment with IFN.
ACKNOWLEDGMENTS
We thank Dr. Wataru Ogawa (University of Kobe) and Dr. Kohjiro Ueki (University of Tokyo) for kindly providing adenovirus encoding WT-STAT3 and F-STAT3 and adenovirus encoding SOCS1 and SOCS3, respectively.
GRANTS
This work was supported in part by a grant from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.
DISCLOSURES
The authors have nothing to disclose. 
